Search results
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
AbbVie’s Patient Assistance Overview. AbbVie is committed to helping patients get the medicines they need. That’s why we offer patient assistance programs that provide free AbbVie medicines to qualifying patients.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.
May 7, 2024 · AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
1 day ago · July 25 (Reuters) - AbbVie (ABBV.N) increased its profit forecast for 2024 on Thursday after reporting strong sales of immunology drugs and quarterly results that exceeded Wall Street expectations ...
Nov 30, 2023 · ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells.
1 day ago · Full-Year 2024 Outlook. AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.61 - $10.81 to $10.71 - $10.91, which includes an unfavorable impact of $0.60 per share ...
Apr 29, 2022 · Across the two pivotal trials, RINVOQ delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achieving ASAS40 (51% and 44.5% with RINVOQ versus 26% and 18.2% with placebo) at week 14 compared to placebo1. RINVOQ demonstrated significant improvement in signs and symptoms of AS at week 141-4.
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
1 day ago · AbbVie ( ABBV 3.38%) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price ...
